Maintenance therapy containing metformin and/or zyflamend for advanced prostate cancer: A case series

17Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Metformin is derived from galegine, a natural ingredient, and recent studies have suggested that metformin could enhance the antitumor effects of hormone ablative therapy or chemotherapy and reduce prostate cancer-specific mortality. Zyflamend is a combination of herbal extracts that reduces inflammation and comprises turmeric, holy basil, green tea, oregano, ginger, rosemary, Chinese goldthread, hu zhang, barberry, and basil skullcap. We propose a maintenance regimen with metformin and/or Zyflamend that targets cancer stem cells and the tumor microenvironment to keep the cancer dormant and prevent it from activation from dormancy. Herein, we report the clinical course of four patients who experienced a clinical response after treatment with metformin and/or Zyflamend.

Cite

CITATION STYLE

APA

Bilen, M. A., Lin, S. H., Tang, D. G., Parikh, K., Lee, M. H., Yeung, S. C. J., & Tu, S. M. (2015). Maintenance therapy containing metformin and/or zyflamend for advanced prostate cancer: A case series. Case Reports in Oncological Medicine, 2015. https://doi.org/10.1155/2015/471861

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free